Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC

Condition:   Breast Cancer Intervention:   Drug: Aromatase Inhibitor and Palbociclib Sponsor:   Sidney Kimmel Comprehensive Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials